{"prompt": "['36', 'MC1488 WEE1', 'MCCC', 'CTCAE', 'System/Organ/Class', 'ADVERSE EVENT', 'AGENT', 'ACTION**', '(SOC)', 'BASED ON INTERVAL ADVERSE EVENT*', 'Blood and Lymphatic', 'Febrile neutropenia >', 'AZD1775', 'May omit dose until fever has resolved or', 'System Disorders', 'Grade 3', 'returned to baseline. Dose to be restarted', 'at same dose level. Treating physician', 'may discuss possible dose reduction with', 'one of the study chairs after the patient', 'has completed 2 cycles.', 'If clinical benefit is derived, AZD1775', 'may be continued if the infection is', 'managed/controlled with appropriate', 'medical intervention.', 'Investigations', 'Neutrophil & Platelet', 'AZD1775', 'Omit dose until ANC and/or platelets', 'count decrease > grade', 'have recovered to < grade 2.', '4', 'If clinical benefit is derived, AZD1775', 'NOTE: only applicable', 'may be continued if not recovered to <', 'for patients with', 'grade 2 after discussion of treating', 'absolute neutrophil', 'physician and study chair.', 'count (ANC) of >', '1000mm\u00b3 and platelet', 'count > 100,000/mm\u00b3 at', 'baseline (i.e. MDS', 'patients)', 'Investigations', 'Creatinine increased', 'AZD1775', 'Omit dose until resolved to < grade 1,', 'Grade 2', 'then:', 'If resolved in 7 days, then maintain', 'dose level', 'If resolved in > 7 days, then decrease', 'by 1 dose level', '[If clinical benefit is derived, AZD1775', 'may be continued if the renal function is', 'elevated but stable]', 'AraC', 'Continue treatment at current dose level', 'Creatinine increased', 'AZD1775', 'Omit dose until resolved to VI grade 1,', 'Grade 3 and 4', 'then decrease dose by 1 dose level', 'AraC', 'Omit dose until resolved to VI grade 1,', 'then decrease dose by 1 dose level']['37', 'MC1488 WEE1', 'MCCC', 'Use the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0* unless', 'otherwise specified <<', 'CTCAE', 'System/Organ/Class', 'ADVERSE EVENT', 'AGENT', 'ACTION**', '(SOC)', 'Investigations', 'Blood bilirubin', 'AZD1775', 'Omit dose until resolved to VI grade 1,', 'increased > Grade 3', 'then:', 'If resolved in 7 days, then maintain', 'dose level', 'If resolved in > 7 days, then decrease', 'by 1 dose level', 'AraC', 'Continue treatment at next lower dose', 'level', 'Blood bilirubin', 'AZD1775', 'Omit dose until resolved to VI grade 1,', 'increased Grade 4', 'then decrease dose by 1 dose level', 'AraC', 'Continue treatment at Dose level - lonce', 'resolved to VI Grade 1', 'Alanine', 'AZD1775', 'Omit dose until resolved to VI grade 1 or', 'aminotransferase', 'baseline then:', '(ALT) increased and/or', 'If resolved in < 7 days, then maintain', 'Aspartate', 'dose level', 'aminotransferase (AST)', 'increased Grade 3', 'If resolved in > 7 days, then decrease', 'dose by 1 dose level', 'AraC', 'Continue treatment at next lower dose', 'level', 'Alanine', 'AZD1775', 'Omit dose until resolved to VI grade 1 or', 'aminotransferase', 'baseline, then decrease dose by 1 dose', '(ALT) increased and/or', 'level', 'Aspartate', 'AraC', 'Continue treatment at Dose level - -1', 'aminotransferase (AST)', 'increased Grade 4', 'Cardiac Disorders', 'Cardiac disorders -', 'AZD1775', 'Omit dose and discontinue patient from', 'Other > Grade 4', 'study', 'Other Non-', 'Grade 4', 'AZD1775', 'Omit drug and follow patient at least', 'Hematologic events', 'weekly or at least every other week until', 'adverse event has resolved to grade 2,', 'restart drug at next lower dose level.', 'AT TIME OF RETREATMENT']\n\n###\n\n", "completion": "END"}